Eradication Begins With Molecular Diagnostics Becoming The Standard of Care in Resource Limited Settings
Bienvenue
Welcome
Eradicus is a molecular diagnostics R&D and manufacturing company that exists for the sole mission of making molecular diagnostics highly accessible across resource limited settings.
Eradicus
At A Glance
We were founded in 2019 in Gémenos, France.
​
We grew exponentially during the COVID-19 pandemic principally due to our unique approach of enhancing accessibility of molecular diagnostic testing across developing and developed economies.
​
Since 2020, we have focused solely on R&D of cutting-edge technology platforms and IVD designs for a large variety of infectious pathogens.
>5 million
IVD Medical Devices Manufactured
>70
Infectious Pathogens Covered by Our R&D Pipeline
ISO
13485
Manufacturing
Accreditation
>100
In-Vitro Diagnostic Devices Under
Development
Gémenos, France
Research Headquarters
Gurugram, India
Development and Manufacturing
Headquarters
Technological Expertise & Differentiation
At Eradicus our R&D strategy is based on developing cutting-edge technologies that cut-short processing times and build in-house capabilities to support price disruptions on gold-standard chemistries.
​
Real Time Loop Mediated Isothermal Amplification 'RT-LAMP' is a molecular biology based chemistry that cleverly uses a specific oligonucleotide assay design methodology to detect DNA/RNA nucleic acids in under 30 minutes (in comparison RT-PCR typically takes >90 minutes).
​
We are one of only a handful of companies across the world that has the technical know-how to develop in-vitro diagnostic assays on the basis of RT-LAMP chemistry.
High-Throughput R&D Pipeline
With over 70 infectious pathogens and over 100 IVD designs across RT-LAMP and RT-PCR platforms, Eradicus is now maturing its designs into regulatory approved IVD medical devices.
IVD Medical Device Update
In 2024, we will begin transforming the molecular testing landscape for Hepatitis B Virus in India.
It is estimated that more 30 million people were infected in India in 2022. An estimated 254 million people are living with hepatitis B worldwide, and 6000 people are newly infected with viral hepatitis (HBV and HCV combined) each day.
​
An estimated number of deaths from viral hepatitis increased from 1.1 million deaths in 2019 to 1.3 million in 2022. Hepatitis B caused 83% of these deaths.
​
The growth and access to molecular testing for treatment monitoring of Hepatitis B virus is seriously limited in India due to costs. Presently the cost of HBV nucleic acid tests (NAT) for quantification of HBV DNA to clinical laboratories ranges between INR 800 to INR 1200.
​
Our intention is to drastically lower input costs for clinical testing laboratories and work with public and private stake-holders to improve patient accessibility to testing.
​
Note: CitaNAT HBV is presently under regulatory review for marketing authorisation in India.